Use of quetiapine in child and adolescent populations - Response to letter from Dr Lambe

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 11, 2013, Pages 1084-1085

  Monasterio, Erik ^a   McKean, Andrew ^a  

^a Hillmorton Hospital   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADVERSE OUTCOME; ANXIETY DISORDER; CANADA; CHILD CARE; CHILD PSYCHIATRY; CHILDHOOD OBESITY; DECISION MAKING; DEPRESSION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FUNDING; HEALTH SURVEY; HUMAN; INFORMED CONSENT; INSOMNIA; LETTER; MEDICAL CARE; MENTAL HEALTH CARE; METABOLIC DISORDER; MOTOR DYSFUNCTION; OBESITY; OFF LABEL DRUG USE; PRESCRIPTION; SEDATION; SIDE EFFECT; SOCIAL STATUS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; HUMANS; MARKETING;

EID: 84887450918     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413498274     Document Type: Letter

References (14)

1. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety. 2011 ; 20: 177-184
2. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association. 2009 ; 302: 1765-1773
3. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Affairs. 2009 ; 28: w770 - w781
4. Domino ME, Swartz MS. Who are the new users of antipsychotic medications?. Psychiatric Services. 2008 ; 59: 507-514
5. Kalverdijk L, Tobi H, van den Berg P, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatric Services. 2008 ; 59: 554-560
6. Lambe J. Response to 'Quetiapine use: Science or clever marketing?'. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 1086
7. McKean A, Monasterio E. Off-label use of atypical antipsychotics. CNS Drugs. 2012 ; 26: 383-390
8. McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: Safety guidelines and recommendations. Clinical Psychology Review. 2011 ; 31: 465-471
9. MonasterioEMcKeanA (2011) Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. The New Zealand Medical Journal124. Available at: www.nzma.org.nz/journal/124-1336/4700 (accessed 28 May 2013).
10. Monasterio E, McKean A. Quetiapine use: Science or clever marketing?. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 96-97
11. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry. 2006 ; 63: 679-685
12. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. Journal of the American Academy of Child & Adolescent Psychiatry. 2010 ; 49: 13-23
13. Panagiotopoulos C, Ronsley R, Elbe D, et al. First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2010 ; 19: 124-137
14. WilsonD (2010) Side effects may include lawsuits. The New York Times, 2October. Available at: www.nytimes.com/2010/10/03/business/03psych.html (accessed 28 May 2013).